Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
First Opinion
Coronavirus
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Exclusive
STAT+

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

  • Nicholas Florko
  • Matthew Herper

By Nicholas Florko and Matthew Herper May 14, 2020

Reprints
Dr. Michelle McMurry-Heath
Michelle McMurry-Heath has been named the new CEO of BIO. Melissa Lyttle for STAT

WASHINGTON — Michelle McMurry-Heath doesn’t talk about biotech the way her peers do.

Where other executives and experts might bring up “access,” and “reimbursement,” McMurry-Heath talks about fairness and ethics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Nicholas Florko

Nicholas Florko

Reporter, Commercial Determinants of Health

Nicholas Florko reports on the commercial determinants of health.

Matthew Herper

Matthew Herper

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

Tags

I was laid off from a public health job.…
I was laid off from a public health job. Trust me, tech layoffs are different
They were the 10% left out of life-changing treatments.…
They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally…
Surgery that launched Ben Carson’s fame ended poorly for…
Surgery that launched Ben Carson’s fame ended poorly for twins
Turkish court hands Novartis and Roche a rare win…
Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye…
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: ALS Association and its chapters battle over money…
Pharmalittle: ALS Association and its chapters battle over money and priorities; eye drops recalled over links…

Comments are closed.

Recommended Stories